BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33781217)

  • 1. Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
    Norvilas R; Dirse V; Semaskeviciene R; Mickeviciute O; Gineikiene E; Stoskus M; Vaitkeviciene G; Rascon J; Griskevicius L
    BMC Cancer; 2021 Mar; 21(1):326. PubMed ID: 33781217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
    Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
    Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
    J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
    Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.
    Moreno Lorenzana D; Juárez Velázquez MDR; Reyes León A; Martínez Anaya D; Hernández Monterde A; Salas Labadía C; Navarrete Meneses MDP; Zapata Tarrés M; Juárez Villegas L; Jarquín Ramírez B; Cárdenas Cardós R; Herrera Almanza M; Paredes Aguilera R; Pérez Vera P
    J Pathol Clin Res; 2021 Jul; 7(4):410-421. PubMed ID: 33890726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
    den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
    Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why and how to treat Ph-like ALL?
    Roberts KG
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.
    Venn NC; Huang L; Hovorková L; Muskovic W; Wong M; Law T; Heatley SL; Khaw SL; Revesz T; Dalla Pozza L; Shaw PJ; Fraser C; Moore AS; Cross S; Bendak K; Norris MD; Henderson MJ; White DL; Cowley MJ; Trahair TN; Zuna J; Sutton R
    Br J Cancer; 2022 Sep; 127(5):908-915. PubMed ID: 35650277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
    Pui CH; Roberts KG; Yang JJ; Mullighan CG
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
    Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
    Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
    Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
    Moorman AV; Barretta E; Butler ER; Ward EJ; Twentyman K; Kirkwood AA; Enshaei A; Schwab C; Creasey T; Leongamornlert D; Papaemmanuil E; Patrick P; Clifton-Hadley L; Patel B; Menne T; McMillan AK; Harrison CJ; Rowntree CJ; Marks DI; Fielding AK
    Leukemia; 2022 Mar; 36(3):625-636. PubMed ID: 34657128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
    Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
    Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Gupta SK; Bakhshi S; Chopra A; Kamal VK
    Leuk Lymphoma; 2018 Aug; 59(8):1899-1904. PubMed ID: 29199525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
    Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
    Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Philadelphia chromosome-like acute lymphoblastic leukemia.
    Tasian SK; Loh ML; Hunger SP
    Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting.
    Gupta DG; Varma N; Sreedharanunni S; Abdulkadir SA; Naseem S; Sachdeva MUS; Binota J; Bose P; Malhotra P; Khadwal A; Varma S
    Br J Cancer; 2023 Jul; 129(1):143-152. PubMed ID: 37156894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
    Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
    Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
    Sánchez R; Ribera J; Morgades M; Ayala R; Onecha E; Ruiz-Heredia Y; Juárez-Rufián A; de Nicolás R; Sánchez-Pina J; Vives S; Zamora L; Mercadal S; Coll R; Cervera M; García O; Ribera JM; Martínez-López J
    Blood Cancer J; 2020 Apr; 10(4):43. PubMed ID: 32332702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.